Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyMon, 10 Jun 2024 18:51:01 +0200Fri, 24 May 2024 17:02:00 +0200Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 19, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rinvoqHuman medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 19, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/rinvoqFri, 24 May 2024 17:02:00 +0200Human medicineRinvoq : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4760-en_1.pdfRinvoq : EPAR - Product informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-4760-en_1.pdfFri, 24 May 2024 17:01:00 +0200Human medicine